^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
1056P - Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study
Published date:
09/13/2021
Excerpt:
CONTRADICTING EVIDENCE: In pts with BRAF V600-Mut and TT, 12 and 18m OS was 62.4% and 50.9% respectively and median OS 18.5m (95% CI 13.3-28.1)…OS in pts treated with CPi seems superior to TT in BRAF V600-Mut group although potential bias must be considered since stage, LDH and ECOG impacted OS.
Source:
Title:
555 Targeted immunotherapy response in acral melanoma patients—A retrospective review from a tertiary care center
Published date:
04/19/2021
Excerpt:
Nineteen patients (20%) with a pathology confirmed diagnosis of ALM received systemic therapy...Immunologic or targeted therapy was used as a primary or adjuvant treatment in 17 patients….All patients with the BRAF V600E mutation experienced disease progression on targeted therapy with an average overall survival of 22.5 months compared to 63.2 months in patients who underwent other treatments such as high dose interferon, or other chemotherapy.
DOI:
10.1016/j.jid.2021.02.582
